User:Marvin O'Neal/VlsE: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
< |
||
| Line 1: | Line 1: | ||
<Structure load='1l8w' size='500' frame='true' align='right' caption='VlsE' scene='Studio:G5SecL01/Main_image_vlse/1'/> | <Structure load='1l8w' size='500' frame='true' align='right' caption='VlsE' scene='Studio:G5SecL01/Main_image_vlse/1'/> | ||
==Overview== | ==Structural Overview== | ||
| Line 7: | Line 7: | ||
==Antigenicity== | |||
The variable regions undergo a recombination event stimulated by the host’s cytokines and absence of those cytokines results in a decreased bacterial burden <ref>PMID:11544329</ref>. This leads to variation with an estimated 10<sup>30</sup> possible combinations, far exceeding the number of antibodies found in the human immune system. While the VR does exhibit antigenicity, this recombination makes it unlikely that enough of a single VR variation will be present in large enough supply to lead to an immunodominant variable region <ref>PMID:10553085</ref>. IR<sub>6</sub>, however, exhibits immunodominance while IR<sub>1</sub>-IR<sub>5</sub> are primarily nonantigenic in humans. Thus, shielding of the immunodominant IR<sub>6</sub> by VR regions not subject to antibody response allows for IR<sub>6</sub> to elicit an immune response while remaining inaccessible to antibody binding. Research suggests that the 26 amino residues of IR<sub>6</sub> may function as a single epitope with a central alpha helical core <ref>PMID:11923306</ref> <ref>PMID:11544329</ref> <ref>PMID:10722641</ref>. | |||
| Line 19: | Line 24: | ||
